Status:
COMPLETED
Digital Intervention Promoting Physical Activity Among Obese People (DIPPAO)
Lead Sponsor:
University Hospital, Clermont-Ferrand
Collaborating Sponsors:
SENS laboratory, Univ. Grenoble Alpes
INRAE, UNH, CRNH Auvergne, Clermont Auvergne University
Conditions:
Obesity
Diabete Type 2
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Overweight and obesity are today considered among the most important health risks facing humanity with more than one in two adults overweight or obese in western countries. In addition, Type 2 diabete...
Detailed Description
This trial is a randomized, two-arm intervention design that will examine the efficacy of a digital group-based intervention based on gamification and teamwork among obese and T2DM patients. The exper...
Eligibility Criteria
Inclusion
- Subject affected for obesity (BMI ≥30 kg/m² and \<45 kg/m²) and/or T2DM.
- Subject treated at the University Hospital of Clermont-Ferrand.
- The participants must have an iOS (at least iOS8 version) or Android (at least version 5) smartphone.
- Subjects must also be able to provide informed consent to participate in the research and be covered by health social security.
- Subjects must be native to any physical activity intervention.
- Sufficient proficiency of French will be required to ensure the understanding of the questionnaires.
Exclusion
- Medical or surgical history judged by the investigator to be incompatible with the study.
- Subject with an unstable psychiatric condition.
- Pregnant or breastfeeding women.
- Heavy alcohol consumption (\> 2 to 3 drinks per day depending on gender) or drug addiction.
- Disability or contraindication to PA.
- Subject with cardiorespiratory and/or osteoarticular disorders that limit their ability to perform physical tests or moderate PA for 30 minutes.
- Subject with progressive cardiovascular or neoplastic disease.
- Subject who has presented a major infection in the 3 months prior to inclusion.
- Subject with a known neuro-muscular pathology (i.e., myopathy, myasthenia, rhabdomyolysis, paraplegia, hemiplegia).
- Subject with chronic or acute inflammatory pathology within 3 months prior to inclusion.
- Subject diagnosed and/or treated for schizophrenia, bipolar disorder, major depression.
- Subject deprived of their liberty by judicial or administrative decision.
- Subject refusing to sign the written consent to participate.
- Subject participating in another study.
Key Trial Info
Start Date :
June 10 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 15 2023
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT04887077
Start Date
June 10 2021
End Date
October 15 2023
Last Update
April 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Clermont-Ferrand
Clermont-Ferrand, France, 63000